The global retinal disorder treatment market is anticipated to grow at a CAGR of 11.2% during the forecast period (2023-2030). Retinal disorders have both high prevalence and incidence in the geriatric population and diabetic patients, boosting the retinal disorder treatment market. According to the National Institute of Health (NIH), in April 2022, the major issue in the elderly population is the high prevalence of sight-threatening conditions, age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and cataracts. AMD is the leading cause of blindness in elderly patients in developed countries. In 2020, approximately 196 million people globally were affected by AMD, with a global prevalence of 8.7%. According to the latest predictions, the number of AMD patients will increase to 288 million people in 2040, as a consequence of the exponential increase in population ageing.
Browse the full report description of “Retinal Disorder Treatment Market Size, Share & Trends Analysis Report by Indication (Diabetic Retinopathy, Macular Degeneration, Retinal Detachment, Retinoblastoma and Other), by Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops and Ointments), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Sales), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/retinal-disorder-treatment-market
Geographic atrophy has a devastating impact on patients' lives and can lead to irreversible vision loss. For instance, in August 2023, Astellas Pharma Inc. announced the US (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.
Preclinical assets include an intravitreally based program for dry age-related macular degeneration and a program that targets cone-rod dystrophy. For instance, in June 2023, Beacon Therapeutics launched retinal disease gene therapies. Beacon’s lead clinical asset is AGTC-501, a gene therapy program in phase 2 clinical trials for the treatment of X-linked retinitis pigmentosa (XLRP). Preclinical assets include therapies for dry age-related macular degeneration and cone-rod dystrophy.
Retinopathy of prematurity is a leading cause of childhood blindness globally. Mild cases of retinopathy of prematurity (ROP) may improve without treatment, but some cases require treatment to keep ROP from causing significant visual impairment and even blindness. For instance, in February 2023, Regeneron Pharmaceuticals, Inc. announced that the US FDA has approved EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity. Following this first pediatric approval, EYLEA was indicated to treat five retinal conditions caused by ocular angiogenesis.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Indication
o By Dosage Form
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Allergan, Inc., Bausch Health Companies Inc., Genentech, Inc., Novartis AG, and Regeneron Pharmaceuticals, Inc., among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Retinal Disorder Treatment Market Report Segment
By Indication
By Dosage Form
By Distribution Channel
Global Retinal Disorder Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/retinal-disorder-treatment-market